NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Scenic Biotech

Scenic Biotech

Private
AmsterdamHealthcare & Life Scienceshttps://scenicbiotech.com/

Last Round

Series A

Mar 10, 2022

Total Funding Raised

$48.95M

Company Overview

Scenic Biotech is a biotechnology company that develops modifier therapies to treat genetic disorders by identifying genes that suppress disease-causing mutations.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug discoveryfunctional genomicsgenetic modifierstarget discoveryCell-Seqbiotech R&Dtherapeutic targetsgenetic diseasetarget validationdrug discovery platformgenomics platformbiotech partnershipwet-labdrug discovery servicestarget identification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Scenic Biotech Comparables

Compare Scenic Biotech with similar companies based on industry and business-model similarity.

Scenic Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Myllia Biotechnology
86%
Nucleome Therapeutics
82%
Enhanced Genomics
79%

Scenic Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 10, 2022
GrantJun 23, 2020
Series AJun 5, 2017
SeedMay 6, 2017

Scenic Biotech Investors

Notable investors and investment history

Scenic Biotech investors
InvestorRounds
BioMedPartnersSeries A
Oxford Science EnterprisesSeed, Series A
Eir VenturesSeries A
Vesalius Biocapital PartnersSeries A
Oxford Science EnterprisesSeries A
Inkef CapitalSeries A, Seed
BioGeneration VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 7, 2026

    Partnered with Ono Pharmaceutical for novel therapeutic target discovery.

  • Oct 27, 2025

    Partnered with Secarna Pharmaceuticals to develop novel therapies for genetic diseases.

Scenic Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Scenic Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Scenic Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersAmsterdam
Employee Range40
Year Founded2017
Last FundingMar 10, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.